Coherus Oncology, Inc. (CHRS) Operating cash flow 2016–2025
Coherus Oncology, Inc. (CHRS) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$138.5MFY2025 · since FY2016: -$252.5M → -$138.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$138.5M | -577.7% |
| FY2024 | -$20.4M | +88.3% |
| FY2023 | -$174.9M | +27.5% |
| FY2022 | -$241.1M | -544.2% |
| FY2021 | -$37.4M | -124.3% |
| FY2020 | $154.1M | +443.6% |
| FY2019 | $28.4M | +117.8% |
| FY2018 | -$159.3M | +20.5% |
| FY2017 | -$200.3M | +20.7% |
| FY2016 | -$252.5M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More CHRS financial trends
CHRS RevenueCHRS Net incomeCHRS Net marginCHRS Gross profitCHRS Gross marginCHRS Operating incomeCHRS Operating marginCHRS Free cash flowCHRS Capital expendituresCHRS Return on equityCHRS Stock buybacksCHRS Dividends paidCHRS Total assetsCHRS Total liabilitiesCHRS Shareholders’ equityCHRS overview →